Nivalin (Galantamine Hydrobromide)

Galantamine reversibly blocks the enzyme acetylcholinesterase, which breaks down acetylcholine, thereby increasing acetylcholine levels in the central nervous system. It also binds to nicotinic acetylcholine receptors, enhancing their response and supporting cholinergic neurotransmission that is reduced in Alzheimer’s disease.

The specific dose and titration schedule for Nivalin are determined by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and tolerability. The prescriber will set the appropriate regimen.

Safety data for galantamine in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Nivalin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nivalin (galantamine) is an acetylcholinesterase inhibitor, similar to donepezil and rivastigmine. Compared with these agents, galantamine also offers allosteric modulation of nicotinic receptors, which may provide additional cognitive benefits, though individual response varies and choice depends on clinical judgment.

Store Nivalin at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Nivalin is supplied as an injectable solution for intramuscular, intravenous or subcutaneous administration. The route, volume and rate of injection are determined by the treating physician and should follow aseptic technique and local prescribing guidelines.

Serious adverse events include bradycardia, syncope, severe vomiting leading to dehydration, hepatotoxicity, seizures and allergic reactions such as rash, angioedema or anaphylaxis. Patients should be monitored closely for these signs, especially during dose escalation.

Nivalin is contraindicated in patients with known hypersensitivity to galantamine or any formulation components, those with severe hepatic impairment, and individuals with uncontrolled cardiac conduction disorders or bradyarrhythmias. Clinicians should assess each patient’s medical history before prescribing.